Skip to search boxSkip to navigationSkip to main content

G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease

  • Christina Signoretti
    ,
  • Shun Matsumura
    ,
  • Samuel Fatehi
    ,
  • Melinee D’silva
    ,
  • Rajamma Mathew
    ,
  • Francesca Cendali
*Corresponding author for this work
  • New York Medical College
    ,
  • University of Colorado Anschutz Medical Campus
    ,
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

BACKGROUND: G6PD (glucose-6-phosphate-dehydrogenase) is a key enzyme in the glycolytic pathway and has been implicated in the pathogenesis of cancer and pulmonary hypertension-associated vascular remodeling. Here, we investigated the role of an X-linked G6pd mutation (N126D polymorphism), which is known to increase the risk of cardiovascular disease in individuals from sub-Saharan Africa and many others with African ancestry, in the pathogenesis of pulmonary hypertension induced by a vascular endothelial cell growth factor receptor blocker used for treating cancer. METHODS AND RESULTS: CRISPR-Cas9 genome editing was used to generate the G6pd variant (N126D; G6pdN126D) in rats. A single dose of the vascular endothelial cell growth factor receptor blocker sugen-5416 (SU; 20 mg/kg in DMSO), which is currently in a Phase 2/3 clinical trial for cancer treatment, was subcutaneously injected into G6pdN126D rats and their wild-type littermates. After 8 weeks of normoxic conditions, right ventricular pressure and hypertrophy, pulmonary artery remodeling, the metabolic profile, and cytokine expression were assessed. Right ventricular pressure and pulmonary arterial wall thickness were increased in G6PDN126D+SU/normoxic rats. Simultaneously, levels of oxidized glutathione, inositol triphosphate, and intracellular Ca2+ were increased in the lungs of G6PDN126D+SU/normoxic rats, whereas nitric oxide was decreased. Also increased in G6PDN126D+SU/normoxic rats were pulmonary levels of plasminogen activator inhibitor-1, thrombin-antithrombin complex, and expression of proinflammatory cytokines CCL3 (chemokine [C-C motif] ligand), CCL5, and CCL7. CONCLUSIONS: Our results suggest G6PDN126D increases inositol triphosphate-Ca2+ signaling, inflammation, thrombosis, and hypertrophic pulmonary artery remodeling in SU-treated rats. This suggests an increased risk of vascular endothelial cell growth factor receptor blocker-induced pulmonary hypertension in those carrying this G6PD variant.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Article number

e035174

Journal (Volume, Issue Number)

Journal of the American Heart Association (Volume 13, Issue 19)

Publication milestones

  • Published - 10/01/2024

Publication status

Published - 10/01/2024

ISSN

2047-9980

Publication IDs

  • Scopus: 85205525700
  • PubMed: 39291493

Publication metrics

Metrics

Fractional count
1
Fractional count
0.09
Fractional count
10
Fractional count
0.91
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
9
Captures
9
Usage
91

Funding Details

We would like to thank The University of Michigan Biomedical Research Core Facility for generating the CRISPR-edited rat model. This study was supported by National Heart, Lung, and Blood Institute grants R01HL132574 (S.A.G. and J.M.M.) and R01HL166546 (S.A.G. and J.M.M.). The Zeiss LSM 980 plus Airyscan 2 Confocal System was awarded to New York Medical College through a National Institutes of Health Shared Instrumentation Grant (1S10OD028527-01). This study was supported by National Heart, Lung, and Blood Institute grants R01HL132574 (S.A.G. and J.M.M.) and R01HL166546 (S.A.G. and J.M.M.). The Zeiss LSM 980 plus Airyscan 2 Confocal System was awarded to New York Medical College through a National Institutes of Health Shared Instrumentation Grant (1S10OD028527-01).
FundersFunding numbers
U-M
-
NHLBI
R01HL166546, 1S10OD028527-01, R01HL132574